huATN-658 (MNPR-101) is a humanized monoclonal antibody inhibitor targeting the urokinase-type plasminogen activator receptor (uPAR). It effectively disrupts the interaction between uPAR and integrins, thereby inhibiting tumor cell proliferation, invasion, and migration. huATN-658 shows potential for research in breast cancer, particularly in cases of triple-negative breast cancer.